Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy
about
sameAs
The Spi1/PU.1 transcription factor accelerates replication fork progression by increasing PP1 phosphatase in leukemiaEvaluation of [18F]-ATRi as PET tracer for in vivo imaging of ATR in mouse models of brain cancer.Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancerPersonalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.Targeting the ATR-CHK1 Axis in Cancer TherapyStabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.S-phase checkpoint regulations that preserve replication and chromosome integrity upon dNTP depletion.Chk1 Promotes DNA Damage Response Bypass following Oxidative Stress in a Model of Hydrogen Peroxide-Associated Ulcerative Colitis through JNK Inactivation and Chromatin Binding.Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression.Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer CellsTumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity.Resveratrol inhibits Extranodal NK/T cell lymphoma through activation of DNA damage response pathwayThe impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.The Impact of DNA Repair Pathways in Cancer Biology and Therapy.Potential Anticancer Mechanisms of a Novel EGFR/DNA-Targeting Combi-Molecule (JDF12) against DU145 Prostate Cancer Cells: An iTRAQ-Based Proteomic Analysis.Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy.Molecular Genetic Analysis of Human Endometrial Mesenchymal Stem Cells That Survived Sublethal Heat Shock.Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis.Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.C-Terminal Binding Protein is Involved in Promoting to the Carcinogenesis of Human Glioma.A Functional Signature Ontology (FUSION) screen detects an AMPK inhibitor with selective toxicity toward human colon tumor cells.A novel role for ATR/Rad3 in G1 phase.Deubiquitinating enzyme USP3 controls CHK1 chromatin association and activation.Germline mutation of CHEK2 in neurofibromatosis 1 and 2: Two case reports.Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemiaNon‑thermal plasma inhibits tumor growth and proliferation and enhances the sensitivity to radiation in vitro and in vivoThe intracellular signalosome of PD-L1 in cancer cellsExploring the links between cancer and placenta developmentHMGA2 gene silencing reduces epithelial-mesenchymal transition and lymph node metastasis in cervical cancer through inhibiting the ATR/Chk1 signaling pathwayInvolvement of a coumarin analog AD-013 in the DNA damage response pathways in MCF-7 cells
P2860
Q33913826-DC1C72B2-64FA-41CE-92AD-880F6D1DC83FQ33925006-4C0ED7FC-2B89-4770-B7A7-6131FFA33431Q37743501-B4AC181A-F584-4890-B6B3-D6161D2B0BE6Q38608688-B0BEC390-1667-4BF8-93AD-C013E46082C3Q38660811-C9E75392-86A8-499B-B289-4C10A1B4186DQ38698806-179D136C-1A29-491F-9303-302CEB9600B2Q38817102-78D963A8-38B2-4194-8A1F-1625B02C6870Q38838490-F7501984-8371-4B34-B739-67FD524D9B16Q38989374-388AF386-9341-4428-A1B4-67D3C8062EE1Q39144822-283BB4C9-82B4-4C56-B442-10A9227148C9Q41079709-C5DCE799-4204-40EF-8CDC-5F45DD42ADE3Q41388351-408E97AF-B28F-4E72-9A94-B81A0B03D01FQ41470356-65902CBE-FC0F-422C-9746-27C13BA5B031Q41545189-77602A3B-2C4E-4668-9EF8-8D960278A486Q41674995-78456913-705B-4DCE-9A21-D5106F19ABF3Q42360755-B8C58202-9B0B-4538-8EFB-C7C90C32586FQ42364707-E1056EBE-196A-452D-98BD-0AEA5E7CDD6AQ47156384-C323D95B-EBDC-4B3E-AE0C-6548BC409EDBQ47223079-9776B85C-0FC9-4533-8129-97679AF34380Q48155911-DC346911-E418-48AB-949B-E77B2B2E018EQ49168184-316BCFCB-4E9C-44ED-8ADF-A0CCEE46AD97Q50128397-EF8D690D-4D15-4BFE-ABFF-69B3AB0915E7Q51434672-C9BBD6A4-118F-461F-B846-494B838E4F76Q52680663-140BAC6F-F247-49FF-BAA8-FEA7196BFD00Q52714449-44AD4514-511C-45BB-AB29-85306A0649A8Q53824680-504339C3-B316-4471-9E08-69AA8B05B003Q54976802-77CF078C-03B0-44B6-ADBA-DD23E7D86524Q56355417-9E2068BA-60EB-4E6B-8969-0A748E447248Q57067458-406C9D15-52E3-43C8-8044-A552611AB12CQ57067759-4B2518FF-3D0C-43E6-B914-C83372D38E84Q57160183-62B3C0E6-9745-4453-8405-57489C01AB11Q58733935-7C35FAD7-C86C-4E02-9388-DEECF6AFCBB5Q58796625-6837A440-53FD-4E0B-9EAB-4370EC0B14C6
P2860
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy
@ast
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy
@en
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy
@nl
type
label
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy
@ast
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy
@en
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy
@nl
prefLabel
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy
@ast
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy
@en
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy
@nl
P2860
P3181
P1476
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy
@en
P2093
Florine Obrist
Gwenola Manic
P2860
P304
P3181
P356
10.1080/23723556.2015.1012976
P407
P577
2015-02-23T00:00:00Z